<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04850495</url>
  </required_header>
  <id_info>
    <org_study_id>OSU-20189</org_study_id>
    <secondary_id>NCI-2021-01332</secondary_id>
    <nct_id>NCT04850495</nct_id>
  </id_info>
  <brief_title>Zanubrutinib in Combination With R-CHOP (ZaR-CHOP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma</brief_title>
  <official_title>A Phase Ib Trial of Zanubrutinib in Combination With R-CHOP (ZaR-CHOP) for Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yazeed Sawalha</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ohio State University Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase Ib trial seeks to find out the best dose and possible side effects and/or benefits&#xD;
      of zanubrutinib in combination with the R-CHOP in treating patients with newly diagnosed&#xD;
      diffuse large B-cell lymphoma (DLBCL). Zanubrutinib is designed to block a protein called&#xD;
      Bruton Tyrosine Kinase in order to stop cancer growth. R-CHOP is the acronym for the&#xD;
      combination of five drugs: rituximab, cyclophosphamide, doxorubicin, vincristine and&#xD;
      prednisone. It is the most widely used chemoimmunotherapy regimen for DLBCL and is considered&#xD;
      the standard-of-care treatment for patients with DLBCL. Three of the drugs in R-CHOP&#xD;
      (cyclophosphamide, doxorubicin and vincristine) are chemotherapy drugs. Rituximab is a type&#xD;
      of immunotherapy and prednisone is a type of steroids.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. Determine the safety, toxicity profile and recommended phase 2 dose (RP2D) of zanubrutinib&#xD;
      in combination with R-CHOP (ZaR-CHOP) for patients with previously untreated diffuse large&#xD;
      B-cell lymphoma (DLBCL).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the objective response rate (ORR) (complete and partial responses),&#xD;
      progression-free survival (PFS) and overall survival (OS) of ZaR-CHOP in patients treated at&#xD;
      the RP2D.&#xD;
&#xD;
      II. Provide descriptive data on treatment exposure to zanubrutinib and R-CHOP including&#xD;
      treatment discontinuation rate and relative dose intensity.&#xD;
&#xD;
      OUTLINE: This is a dose de-escalation study of zanubrutinib and fixed-dose R-CHOP regimen&#xD;
      followed by a dose-expansion study.&#xD;
&#xD;
      Patients receive zanubrutinib orally (PO) once or twice daily on days 1-21, rituximab&#xD;
      intravenously (IV) on day 1, cyclophosphamide IV on day 1, doxorubicin hydrochloride IV on&#xD;
      day 1, vincristine sulfate IV on day 1, and prednisone PO QD on days 1-5. Treatment repeats&#xD;
      every 21 days for up to 6 cycles in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed every 6 months for 2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    PI decison&#xD;
  </why_stopped>
  <start_date type="Anticipated">December 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Measured by the Common Terminology Criteria for Adverse Events version 5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Defined as the proportion of patients achieving a complete or partial response. ORR will be reported with a 95% binomial confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>From the start of treatment to time of progression or death, whichever occurs first, assessed up to 24 months</time_frame>
    <description>Will be estimated using the method of Kaplan-Meier, where the estimates at time points of interest will be reported with 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From start of treatment to death from any cause, assessed up to 24 months</time_frame>
    <description>Will be estimated using the method of Kaplan-Meier, where the estimates at time points of interest will be reported with 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zanubrutinib duration of treatment</measure>
    <time_frame>Up to 6 cycles (each cycle is 21 days in length)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zanubrutinib average daily dose</measure>
    <time_frame>Up to 6 cycles (each cycle is 21 days in length)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zanubrutinib discontinuation rate</measure>
    <time_frame>Up to 6 cycles (each cycle is 21 days in length)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zanubrutinib relative dose intensity</measure>
    <time_frame>Up to 6 cycles (each cycle is 21 days in length)</time_frame>
    <description>Defined as the ratio of the amount of a drug actually administered to the amount planned for a fixed time period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone (R-CHOP) cycles received</measure>
    <time_frame>Up to 6 cycles (each cycle is 21 days in length)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R-CHOP discontinuation rates</measure>
    <time_frame>Up to 6 cycles (each cycle is 21 days in length)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R-CHOP relative dose intensity</measure>
    <time_frame>Up to 6 cycles (each cycle is 21 days in length)</time_frame>
    <description>Defined as the ratio of the amount of a drug actually administered to the amount planned for a fixed time period.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Diffuse Large B-Cell Lymphoma</condition>
  <condition>Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma</condition>
  <condition>Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (zanubrutinib, R-CHOP)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive zanubrutinib PO on days 1-21, rituximab IV on day 1, cyclophosphamide IV on day 1, doxorubicin hydrochloride IV on day 1, vincristine sulfate IV on day 1, and prednisone PO QD on days 1-5. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (zanubrutinib, R-CHOP)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamide Monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin Hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (zanubrutinib, R-CHOP)</arm_group_label>
    <other_name>5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)</other_name>
    <other_name>ADM</other_name>
    <other_name>Adriacin</other_name>
    <other_name>Adriamycin</other_name>
    <other_name>Adriamycin Hydrochloride</other_name>
    <other_name>Adriamycin PFS</other_name>
    <other_name>Adriamycin RDF</other_name>
    <other_name>ADRIAMYCIN, HYDROCHLORIDE</other_name>
    <other_name>Adriamycine</other_name>
    <other_name>Adriblastina</other_name>
    <other_name>Adriblastine</other_name>
    <other_name>Adrimedac</other_name>
    <other_name>Chloridrato de Doxorrubicina</other_name>
    <other_name>DOX</other_name>
    <other_name>DOXO-CELL</other_name>
    <other_name>Doxolem</other_name>
    <other_name>Doxorubicin HCl</other_name>
    <other_name>Doxorubicin.HCl</other_name>
    <other_name>Doxorubin</other_name>
    <other_name>Farmiblastina</other_name>
    <other_name>FI 106</other_name>
    <other_name>FI-106</other_name>
    <other_name>hydroxydaunorubicin</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (zanubrutinib, R-CHOP)</arm_group_label>
    <other_name>.delta.1-Cortisone</other_name>
    <other_name>1, 2-Dehydrocortisone</other_name>
    <other_name>Adasone</other_name>
    <other_name>Cortancyl</other_name>
    <other_name>Dacortin</other_name>
    <other_name>DeCortin</other_name>
    <other_name>Decortisyl</other_name>
    <other_name>Decorton</other_name>
    <other_name>Delta 1-Cortisone</other_name>
    <other_name>Delta-Dome</other_name>
    <other_name>Deltacortene</other_name>
    <other_name>Deltacortisone</other_name>
    <other_name>Deltadehydrocortisone</other_name>
    <other_name>Deltasone</other_name>
    <other_name>Deltison</other_name>
    <other_name>Deltra</other_name>
    <other_name>Econosone</other_name>
    <other_name>Lisacort</other_name>
    <other_name>Meprosona-F</other_name>
    <other_name>Metacortandracin</other_name>
    <other_name>Meticorten</other_name>
    <other_name>Ofisolona</other_name>
    <other_name>Orasone</other_name>
    <other_name>Panafcort</other_name>
    <other_name>Panasol-S</other_name>
    <other_name>Paracort</other_name>
    <other_name>Perrigo Prednisone</other_name>
    <other_name>PRED</other_name>
    <other_name>Predicor</other_name>
    <other_name>Predicorten</other_name>
    <other_name>Prednicen-M</other_name>
    <other_name>Prednicort</other_name>
    <other_name>Prednidib</other_name>
    <other_name>Prednilonga</other_name>
    <other_name>Predniment</other_name>
    <other_name>Prednisone Intensol</other_name>
    <other_name>Prednisonum</other_name>
    <other_name>Prednitone</other_name>
    <other_name>Promifen</other_name>
    <other_name>Rayos</other_name>
    <other_name>Servisone</other_name>
    <other_name>SK-Prednisone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (zanubrutinib, R-CHOP)</arm_group_label>
    <other_name>ABP 798</other_name>
    <other_name>BI 695500</other_name>
    <other_name>C2B8 Monoclonal Antibody</other_name>
    <other_name>Chimeric Anti-CD20 Antibody</other_name>
    <other_name>CT-P10</other_name>
    <other_name>IDEC-102</other_name>
    <other_name>IDEC-C2B8</other_name>
    <other_name>IDEC-C2B8 Monoclonal Antibody</other_name>
    <other_name>MabThera</other_name>
    <other_name>Monoclonal Antibody IDEC-C2B8</other_name>
    <other_name>PF-05280586</other_name>
    <other_name>Rituxan</other_name>
    <other_name>Rituximab ABBS</other_name>
    <other_name>Rituximab Biosimilar ABP 798</other_name>
    <other_name>Rituximab Biosimilar BI 695500</other_name>
    <other_name>Rituximab Biosimilar CT-P10</other_name>
    <other_name>Rituximab Biosimilar GB241</other_name>
    <other_name>Rituximab Biosimilar IBI301</other_name>
    <other_name>Rituximab Biosimilar JHL1101</other_name>
    <other_name>Rituximab Biosimilar PF-05280586</other_name>
    <other_name>Rituximab Biosimilar RTXM83</other_name>
    <other_name>Rituximab Biosimilar SAIT101</other_name>
    <other_name>Rituximab Biosimilar SIBP-02</other_name>
    <other_name>rituximab biosimilar TQB2303</other_name>
    <other_name>rituximab-abbs</other_name>
    <other_name>RTXM83</other_name>
    <other_name>Truxima</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (zanubrutinib, R-CHOP)</arm_group_label>
    <other_name>Kyocristine</other_name>
    <other_name>Leurocristine Sulfate</other_name>
    <other_name>Leurocristine, sulfate</other_name>
    <other_name>Oncovin</other_name>
    <other_name>Vincasar</other_name>
    <other_name>Vincosid</other_name>
    <other_name>Vincrex</other_name>
    <other_name>Vincristine, sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zanubrutinib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (zanubrutinib, R-CHOP)</arm_group_label>
    <other_name>BGB-3111</other_name>
    <other_name>Brukinsa</other_name>
    <other_name>BTK-InhB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically confirmed DLBCL, irrespective of cell-of-origin.&#xD;
             Patients with previously diagnosed indolent lymphoma (follicular lymphoma and marginal&#xD;
             zone lymphoma but not small lymphocytic lymphoma) who have transformed to DLBCL are&#xD;
             eligible only if they have not previously been treated for indolent lymphoma except&#xD;
             for local radiation for early-stage disease&#xD;
&#xD;
          -  Patients may have received brief treatment with glucocorticoids (up to 250 mg/day&#xD;
             prednisone or equivalent for a maximum of 10 days) and/or 1 cycle of chemotherapy such&#xD;
             as R-CHOP (or some component[s] thereof) for the diagnosis of B-cell lymphoma provided&#xD;
             they had staging computed tomography (CT) and/or positron emission tomography (PET)/CT&#xD;
             scans prior to glucocorticoids and/or chemotherapy. Treatment must occur within 28&#xD;
             days prior to enrollment&#xD;
&#xD;
          -  Age &gt;= 18 years. Because no dosing or adverse event data are currently available on&#xD;
             the use of zanubrutinib in combination with R-CHOP in patients &lt;18 years of age,&#xD;
             children are excluded from this study&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2. Performance status&#xD;
             of 3 will be accepted if the impairment is caused by DLBCL complications and&#xD;
             improvement is expected once therapy is initiated&#xD;
&#xD;
          -  Measurable disease (defined as &gt;= 1.5cm in diameter) or at least one PET&#xD;
             fludeoxyglucose F-18 (FDG) avid area of disease&#xD;
&#xD;
          -  Patients must have adequate hematologic, hepatic, and renal function as defined below:&#xD;
&#xD;
          -  Hemoglobin &gt;= 7.0 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt; 1,000/mcL&#xD;
&#xD;
          -  Platelet count &gt; 75,000/mcL&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x the upper limit of the normal range (ULN) (unless due to&#xD;
             Gilbert's disease)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) &lt;&#xD;
             2.5 x institutional ULN&#xD;
&#xD;
          -  Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) &lt; 2.5 x&#xD;
             institutional ULN&#xD;
&#xD;
          -  Creatinine clearance &gt; 40 mL/min calculated by Cockcroft-Gault&#xD;
&#xD;
          -  Adequate cardiac function with a left ventricular ejection fraction (LVEF) &gt;= 50% as&#xD;
             assessed by echocardiogram or MUGA (Multigated acquisition scan)&#xD;
&#xD;
          -  The effects of zanubrutinib on the developing human fetus are unknown. For this reason&#xD;
             and because chemotherapeutic agents used in this study are known to be teratogenic,&#xD;
             women of child-bearing potential and men must agree to use adequate contraception&#xD;
             (double barrier method of birth control or abstinence) 2 weeks prior to initiation of&#xD;
             treatment, for the duration of study participation and for 3 months after completing&#xD;
             treatment. Should a woman become pregnant or suspect that she is pregnant while she or&#xD;
             her partner is participating in this study, she should inform the treating physician&#xD;
             immediately. Men must agree to refrain from sperm donation for at least 90 days after&#xD;
             the last dose of zanubrutinib&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum (beta-human chorionic&#xD;
             gonadotropin [beta-hCG]) or urine pregnancy test at screening. Women who are pregnant&#xD;
             or breastfeeding are ineligible for this study&#xD;
&#xD;
          -  Patients must have the ability to understand and the willingness to sign a written&#xD;
             informed consent document and Health Insurance Portability and Accountability Act&#xD;
             (HIPAA) consent document. Voluntary written consent must be given before performance&#xD;
             of any study-related procedure not part of standard medical care, with the&#xD;
             understanding that consent may be withdrawn by the patient at any time without&#xD;
             prejudice to future medical care&#xD;
&#xD;
          -  International Prognostic Index must be documented:&#xD;
&#xD;
               -  ECOG performance status &gt;= 2 (1 point)&#xD;
&#xD;
               -  Age &gt;= 60 (1 point)&#xD;
&#xD;
               -  &gt;= 2 extranodal sites (1 point)&#xD;
&#xD;
               -  Lactate dehydrogenase measurement (LDH) &gt; upper limit of normal (1 point)&#xD;
&#xD;
               -  Ann Arbor Stage III or IV (1 point)&#xD;
&#xD;
               -  Is there evidence of transformation from indolent lymphoma?&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major surgery within 4 weeks before Day 1, Cycle 1 of treatment&#xD;
&#xD;
          -  Prior anthracycline use &gt;= 150 mg/m^2&#xD;
&#xD;
          -  Known central nervous system (CNS) involvement. Patients at high risk for secondary&#xD;
             CNS involvement but without neurologic symptoms suspected to be due to lymphoma are&#xD;
             allowed to be enrolled and receive intrathecal chemotherapy with methotrexate,&#xD;
             cytarabine, and/or glucocorticoids. CNS prophylaxis with IV methotrexate is NOT&#xD;
             permitted in this study. Patients who are enrolled and subsequently identified to have&#xD;
             pathologic confirmation of CNS involvement by lymphoma may be continued on the study&#xD;
             at the discretion of the principal investigator&#xD;
&#xD;
          -  Active systemic bacterial, fungal or viral infection except for localized fungal&#xD;
             infections of skin or nails. Patients with resolving infections such as urinary tract,&#xD;
             respiratory, or skin infections may be enrolled if clinically improving. NOTE:&#xD;
             patients may be receiving prophylactic antiviral or antibacterial therapies at the&#xD;
             investigator's discretion&#xD;
&#xD;
          -  Evidence of current uncontrolled or symptomatic cardiovascular conditions, including,&#xD;
             uncontrolled cardiac arrhythmias, history of or symptomatic congestive heart failure&#xD;
             (New York Heart Association [NYHA] Class III or greater), unstable angina, or&#xD;
             myocardial infarction within the past 6 months. Poorly controlled or clinically&#xD;
             significant atherosclerotic vascular disease including angioplasty, cardiac or&#xD;
             vascular stenting within 6 months of enrollment&#xD;
&#xD;
          -  History of cerebrovascular accident or transient ischemic attack within the 6 months&#xD;
             before Day 1, Cycle 1 of treatment&#xD;
&#xD;
          -  Any prior history of intracranial hemorrhage&#xD;
&#xD;
          -  Known bleeding diatheses or platelet dysfunction disorders&#xD;
&#xD;
          -  Known gastrointestinal (GI) disease or gastrointestinal procedure that will&#xD;
             significantly interfere with the oral absorption or tolerance of zanubrutinib&#xD;
             including the inability to swallow pills/capsules&#xD;
&#xD;
          -  Any serious medical or psychiatric illness that could, in the investigator's opinion,&#xD;
             potentially interfere with the completion of treatment according to this protocol&#xD;
&#xD;
          -  Known allergy to any of the study medications, their analogues, or excipients in the&#xD;
             various formulations of any agent&#xD;
&#xD;
          -  Evidence of prior malignancy except for: adequately treated non-melanoma skin cancer,&#xD;
             adequately treated in situ carcinoma, low-grade prostate carcinoma (Gleason grade =&lt;&#xD;
             6) managed with observation that has been stable for at least 6 months, or any&#xD;
             malignancy treated with curative intent and continuously disease-free for at least 3&#xD;
             years&#xD;
&#xD;
          -  Participation in other interventional clinical trials, including those with other&#xD;
             investigational agents not included in this trial, within 21 days of Day 1, Cycle 1 of&#xD;
             this trial. Also excluded are patients who are receiving any other investigational&#xD;
             agents outside of a clinical trial&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV), active hepatitis C infection (HCV&#xD;
             ribonucleic acid [RNA] polymerase chain reaction [PCR]-positive) and/or active&#xD;
             hepatitis B infections (HBV deoxyribonucleic acid [DNA] PCR-positive). If hepatitis B&#xD;
             virus core (HBc) antibody is positive, the patient must be evaluated for the presence&#xD;
             of HBV DNA by PCR. If HCV antibody is positive, the patient must be evaluated for the&#xD;
             presence of HCV RNA by PCR. Patients with positive HBc antibody and negative HBV DNA&#xD;
             by PCR are eligible. Patients with positive HCV antibody and negative HCV RNA by PCR&#xD;
             are eligible&#xD;
&#xD;
          -  Pregnant or breastfeeding women are excluded from this study. Because there is an&#xD;
             unknown, but potential risk for adverse events in nursing infants secondary to&#xD;
             treatment of the mother with zanubrutinib, breastfeeding should be discontinued if the&#xD;
             mother is treated with zanubrutinib. These potential risks may also apply to other&#xD;
             agents used in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yazeed Sawalha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://cancer.osu.edu</url>
    <description>The Jamesline</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 14, 2021</study_first_submitted>
  <study_first_submitted_qc>April 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2021</study_first_posted>
  <last_update_submitted>October 5, 2021</last_update_submitted>
  <last_update_submitted_qc>October 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University Comprehensive Cancer Center</investigator_affiliation>
    <investigator_full_name>Yazeed Sawalha</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cortisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Zanubrutinib</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

